key: cord-0314031-qdmkx03t authors: Lucas, C.; Vogels, C. B. F.; Yildirim, I.; Rothman, J.; Lu, P.; Monteiro, V.; Gelhausen, J. R.; Campbell, M.; Silva, J.; Tabachikova, A.; Munker, M. C.; Breban, M. I.; Fauver, J. R.; Mohanty, S.; Huang, J.; Yale SARS-CoV-2 Genomic Surveillance Initiative,; Shaw, A. C.; Ko, A.; Omer, S. B.; Grubaugh, N. D.; Iwasaki, A. title: Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity in uninfected and previously infected individuals date: 2021-07-18 journal: nan DOI: 10.1101/2021.07.14.21260307 sha: 9b5ad18903cd25e475aa63b1ccfbb041a03e4428 doc_id: 314031 cord_uid: qdmkx03t The emergence of SARS-CoV-2 variants with mutations in major neutralizing antibody-binding sites can affect humoral immunity induced by infection or vaccination (1-6). We analysed the development of anti-SARS-CoV-2 antibody and T cell responses in previously infected (recovered) or uninfected (naive) individuals that received mRNA vaccines to SARS-CoV-2. While previously infected individuals sustained higher antibody titers than uninfected individuals post-vaccination, the latter reached comparable levels of neutralization responses to the ancestral strain than previously infected individuals 7 days after the second vaccine dose. T cell activation markers measured upon spike or nucleocapsid peptide in vitro stimulation showed a progressive increase after vaccination in the time-points analysed. Comprehensive analysis of plasma neutralization using 16 authentic isolates of distinct locally circulating SARS-CoV-2 variants revealed a range of reduction in the neutralization capacity associated with specific mutations in the spike gene: lineages with E484K and N501Y/T (e.g., B.1.351 and P.1) had the greatest reduction, followed by lineages with L452R (e.g., B.1.617.2) or with E484K (without N501Y/T). While both groups retained neutralization capacity against all variants, plasma from previously infected vaccinated individuals displayed overall better neutralization capacity when compared to plasma from uninfected individuals that also received two vaccine doses, pointing to vaccine boosters as a relevant future strategy to alleviate the impact of emerging variants on antibody neutralizing activity. . We determined antibody profiles, using both ELISA and neutralizations assays; and assessed cellular immune response, profiled by flow cytometry using frozen PBMCs. We found that mRNA vaccines induced high titers of virus-specific antibodies that declined over time, as previously reported 6, 11 (Figure 1b, c) . After the first vaccine dose, over 97% vaccinated participants developed virus-specific IgG titers, which increased to 100% after the second dose. IgG titers against the S protein, spike subunit 1 (S1), and receptor binding domain (RBD) peaked 7 days post second vaccination dose (Figure 1 b, c) . No differences were observed in antibody levels between vaccinated participants of different sexes and after stratification by age (Extended Data Figure 1a ). Consistent with previous reports 7, 12 , we found that virus-specific IgG levels were significantly higher in the previously infected vaccinated group than the uninfected vaccinated group (Extended Data Figure 1b and Figure 1c ). As expected, given the absence of sequences encoding nucleocapsid (N) antigens in the mRNA vaccines, anti-N antibody titers remain stable over time for previously infected vaccinated individuals, and were not affected by vaccination in both the uninfected and previously infected groups (Figure 1 b, c) . We next assessed plasma neutralization activity longitudinally against an authentic SARS-CoV-2 strain USA-WA1/2020 (lineage A), with a similar S gene amino acid sequence as Wuhan-Hu-1 used for the mRNA vaccine design, by a 50% plaque-reduction neutralization (PRNT50) assay. Neutralization activity directly correlates with anti-S and anti-RBD antibody titers, also peaking at 7 days post second dose (Figure 1 d, e) . However, both groups displayed similar neutralization titers against the lineage A virus isolate at the peak of response (Figure 1 d, e). Our data indicate that despite faster and more exuberant antibody responses to viral proteins by previously infected vaccinated than uninfected vaccinated individuals, vaccination led to overall similar levels of neutralizing antibodies (NAb) after the second dose. A robust T cell response has also been linked to efficient protective immunity against SARS-CoV-2 [13] [14] [15] . Hence, we next longitudinally analyzed S-and N-reactive T cells responses in vaccinated individuals. To detect low-frequency peptide-specific T cell populations, we first expanded antigenic-specific T cells by stimulating PBMCs from vaccinated individuals with S and N peptide pools ex vivo for 6 days, followed by restimulation with the same peptide pools and analysis of activation markers after 12 hours. To cover the entire S protein, two peptide pools were used (S-I and S-II), while a single peptide pool was used for the nucleocapsid stimulation. S-reactive CD4 + and CD8 + T cells increased over time following vaccination (Figure 2 a, b) , as evidenced by an increase in cells expressing the activation markers CD38 and HLA-DR; no differences were observed between the previously infected and uninfected vaccinated groups. Consistent with previous reports 16, 17 , S-reactive CD4 + T cell responses were comparable among full-length lineage A and P.1 virus isolates. In contrast, S-reactive CD8 + T cell responses were only observed to lineage A, and not P. To investigate potential differences in NAb escape between the SARS-CoV-2 variants, we analyzed the neutralization capacity of plasma samples from vaccinated individuals against a panel of 18 genetically distinct and authentic SARS-CoV-2 isolates. Among the isolates, 16 were from our Connecticut SARS-CoV-2 genomic surveillance program representing variants from the same geographical region as our HCW cohort 18 20 Table 2 ). Except lineage A, all isolates (lineages B, P, and R) have the S gene D614G mutation located in the receptor-binding motif, which has been reported not to impact vaccine-elicited neutralization 21 . For each isolate we highlight additional key amino acid differences concentrated in the subunit 1, including RBD and additional antigenic sites of the S protein ( Figure 3a ): L18F and domain (NTD); K417N and L452R located in the epitopes of the RBD; S477N, T478K, E484K/Q, and N501T/Y located in the RBD-ACE2 interface; and P681H/R located in the furin cleavage site. A full list of amino acid substitutions and deletions from all genes is provided in Extended Data Table 2 . We used a PRNT50 assay to determine the neutralization titers of plasma collected from 32 HCWs 28 days after the second vaccination dose to each isolate. When comparing vaccine-induced neutralization against the different isolates in comparison to the lineage A virus isolate, we observed significantly reduced PRNT50 titers for 12 out of the 17 isolates, and the rank order of reduced neutralization mostly clustered by key S gene amino acid differences (Figure 3a) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; largest individual impact, but the added effects of E484K and N501Y make viruses with this combination perhaps the most concerning for vaccines. Although virus-specific factors may play a significant role in neutralization, differences in neutralization activity between individual vaccinated HCWs were much larger (up to ~2 log PRNT50 titers) than differences among virus isolates (mostly <1 log; Figure 3a ). By tracking PRNT50 titers from each HCW, we found the vaccinated individuals with high neutralization activity for the lineage A virus isolate are typically on the higher end of neutralization for all variants ( Figure 3c ). Moreover, two vaccinated HCWs did not develop neutralizing antibodies against any of the virus isolates, including lineage A (Figure 3c ), despite the production of virus-specific antibodies (Figure 1a All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; Human NAbs against SARS-CoV-2 can be categorized as belonging to four classes on the basis of their target regions on the RBD. Although the RBD is immunodominant, there is evidence for a substantial role of other spike regions in antigenicity, most notably the NTD supersite [22] [23] [24] . These antibodies target epitopes that are closely associated with NTD and RBD residues L18 and Δ H69/V70, and K417, L452, S477, T478, E484 and N501. Previous studies using pseudovirus constructs reported a significant impact of single S amino acid substitutions, including S477N, E484K, and N501Y, located at the RBD-ACE2 interface, in the neutralization activity of plasma from vaccinated individuals [1] [2] [3] [4] [5] . Using a large panel of genetically diverse authentic SARS-CoV-2 isolates, we found that decreases in mRNA vaccine-induced neutralization capacity could be generally categorized into three tiers based on the presence of L452R, E484K, and/or N501Y/T. Tier 1, which we found to decrease neutralization titers by >10 fold in previously uninfected vaccinated individuals, includes lineages with both the E484K and N501Y/T mutations such as B.1.351 (Beta) and P.1 (Gamma), further supporting their importance in regards to vaccines. Interestingly, we also found that a generic lineage B.1 isolate with E484K and N501T, and a rare B.1.1.7 (Alpha) isolate with E484K (also with the common N501Y mutation) have similar impacts on neutralization as B.1.351 and P.1. While the combinations of mutations in the B.1 and B.1.1.7 with E484K isolates likely do not increase transmissibility, the additive effects of these two mutations supports that surveillance programs should track all viruses with E484K and N501Y/T in addition to variants of concern/interest. Tier 2 consists of SARS-CoV-2 lineages with the L452R mutation, and tier 3 consists of lineages with E484K but without N501Y/T. Notably, lineages with the L452R mutation include B.1.617.2 (Delta). We found that B.1.617.2 had a comparatively modest impact on neutralization titers: 6.9 fold decrease in uninfected and 1.5 fold decrease in previously infected vaccinated individuals (2.5 fold decrease combined) as compared to lineage A. From these data, we expect that most fully vaccinated individuals will be protected against B.1.617.2, and that the rise in vaccine-breakthroughs associated with this variant are more likely associated with its high transmissibility [25] [26] [27] [28] S477N ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint The discrepancies of our results compared to other studies may point to the importance of using fully intact authentic virus for neutralization assays to detect effects of epistasis among virus mutations on neutralization assays. Nevertheless, it remains possible that additional factors also contribute to some of the discrepancies between our observations and those of previous studies, including the composition of our cohorts, predominantly young Caucasian women. Discrepancies between cohorts could also account for subtle differences in T cell responses observed in our study versus the ones recently reported by Alter et al., and Tarke et al. While we observed decreased cross-reactivity of S-reactive CD8 + T cells against P.1 S peptides, the above studies found T cell responses are largely preserved against variants 16, 17 . In addition to cohort composition, we used overlapping peptide pools in our assays, hence, we cannot rule out the possibility that some mutations affect antigen All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. Dunnett's method. Neutralization capacity to the variants was compared to neutralization capacity All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint against the ancestral strain. Boxes represent mean values ± standard deviations. Dotted line indicates the mean value of PRNT50 to ancestral strain. Variants were grouped giving specific-spike mutations and are coloured accordingly. ****p < .0001 ***p < .001 **p < .01*p < .05. b, Neutralization titer comparison among vaccinated participants previously infected or not to SARS-CoV-2. Significance was accessed using unpaired t-test. Boxes represent mean values ± standard deviations. (-) Vaccinated-uninfected, n=17; (+) Vaccinated-Previously infected, n=15. Each dot represents a single individual **p < .01*p < .05. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint Whole blood was collected in heparinized CPT blood vacutainers (BD; # BDAM362780) and kept on gentle agitation until processing. All blood was processed on the day of collection in a single step standardised method. Plasma samples were collected after centrifugation of whole blood at 600 g for 20 min at room temperature (RT) without brake. The undiluted plasma was transferred to 15-ml polypropylene conical tubes, and aliquoted and stored at −80 °C for subsequent analysis. The PBMC layer was isolated according to the manufacturer's instructions. Cells were washed twice with PBS before counting. Pelleted cells were briefly treated with ACK lysis buffer for 2 min and then counted. Percentage viability was estimated using standard Trypan blue staining and an automated cell counter (Thermo-Fisher, #AMQAX1000). PBMCs were stored at -80 °C for subsequent analysis. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint ELISAs were performed as previously described 40 Stimulation controls were performed with PBS (unstimulated). Peptide pools were used at 1 μ g/ml per peptide. Incubation was performed at 37 °C, 5% CO2 for 6 days. On day 6, cells were restimulated with 10ug/ml per peptide and subsequently incubated for 12h, being the last 6 h in the presence of 10 μ g/ml brefeldin A (Sigma-Aldrich). Following this incubation, cells were washed with PBS 2 mM EDTA and prepared for analysis by flow cytometry. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. Medium (DMEM) supplemented with 1% sodium pyruvate (NEAA) and 5% fetal bovine serum (FBS) at 37°C and 5% CO2. The cell line was obtained from the ATCC and has been tested negative for contamination with mycoplasma. SARS-CoV-2 lineage A(USA-WA1/2020), was obtained from BEI Resources (#NR-52281) and was amplified in TMPRSS2-VeroE6. Cells were infected at a MOI 0.01 for three days to generate a working stock and after incubation the supernatant was clarified by centrifugation (450 g × 5 min), and filtered through a 0.45-micron filter. The pelleted virus was then resuspended in PBS and aliquoted for storage at −80°C. Viral titers were measured by standard plaque assay using TMPRSS2-VeroE6. Briefly, 300 µl of serial fold virus dilutions were used to infect Vero E6 cells in MEM supplemented NaHCO3, 4% FBS 0.6% Avicel RC-581. Plaques were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; resolved at 48h post-infection by fixing in 10% formaldehyde for 1h followed by 0.5% crystal violet in 20% ethanol staining. Plates were rinsed in water to plaques enumeration. All experiments were performed in a biosafety level 3 laboratory with approval from the Yale Environmental Health and Safety office. SARS-CoV-2 samples were sequenced as part of the Yale Genomic Surveillance Initiative's weekly surveillance program in Connecticut, United States 33 . Lineages were sequenced and isolated as described previously 34 . In brief, nucleic acid was extracted from de-identified remnant nasopharyngeal swabs and tested with our multiplexed RT-qPCR variant assay to select samples with a N1 cycle threshold (Ct) value of 35 or lower for sequencing 35, 36 . Libraries were prepared with a slightly adjusted version of the Illumina COVIDSeq Test RUO version. The Yale Center for Genome Analysis sequenced pooled libraries of up to 96 samples on the Illumina NovaSeq (paired-end 150). Data was analyzed and consensus genomes were generated using iVar (version 1.3.1) 37 . Variants of interest and concern, lineages with mutations of concern (E484K), as well as other lineages as controls were selected for virus isolation. In total, 16 viruses were isolated belonging to 12 lineages (Extended Data Figure 3 ; Extended Data Table 2 ). In addition, ancestral lineage A virus and Table 2 ). Key spike amino acid differences were identified based on the outbreak.info mutation tracker 20 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint Vaccinated HCWs sera were isolated as described before and then heat treated for 30 min at 56°C. Sixfold serially diluted plasma, from 1:3 to 1:2430 were incubated with SARS-CoV-2 variants, for 1 h at 37 °C. The mixture was subsequently incubated with TMPRSS2-VeroE6 in a 12-well plate for 1h, for adsorption. Then, cells were overlayed with MEM supplemented NaHCO 3 , 4% FBS 0.6% Avicel mixture. Plaques were resolved at 40 h post infection by fixing in 10% formaldehyde for 1 h followed by staining in 0.5% crystal violet. All experiments were performed in parallel with baseline controls sera, in an established viral concentration to generate 60-120 plaques/well. All analyses of patient samples were conducted using GraphPad Prism 8. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; Extended Data Figure 4 | Gating strategies. Gating strategies are shown for the key cell populations described in Figure 2 and Extended Data Figure 2 . a, Leukocyte gating strategy to identify lymphocytes. T cell surface staining gating strategy to identify CD4 and CD8 T cells, TCR-activated T cells and follicular T cells. b, B cell surface staining gating strategy to identify B cells subsets. Table 1 | SARS-CoV-2 Vaccinated Cohort. Exact counts for each demographic category are displayed in each cell with accompanying standard deviations for each measurement. Percentages of total, where applicable, are provided in parenthesis. In cases where specific demographic information was missing, the total number of patients with complete information used for calculations is provided within the cell. Table 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display t The cop this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals CoV-2 Variant Surveillance SARS-CoV-2 Variant Classifications and Definitions SARS-CoV-2 (hCoV-19) Mutation Reports SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo Convergent antibody responses to SARS-CoV-2 in convalescent individuals SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. bioRxiv (2021) Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. workers, Israel Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York Delayed production of neutralizing antibodies correlates with fatal COVID-19 Food & Drug Administration Real-time public health communication of local SARS-CoV-2 genomic epidemiology A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2 Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar Fitting Linear Mixed-Effects Models Using lme4 No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perp The copyright holder for th this version posted July 18, 2021. ; https://doi.org/10.1101/2021.07.14.21260307 doi: medRxiv preprint Vaccinated-Non-previous infected **** *** **** **** *** *** **** * **** **** ***